No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.

Show other versions (1)

OBJECTIVES: The aim of this study was to test the effects of the KIF6 Trp719Arg polymorphism (rs20455) on vascular risk and response to statin therapy in 18,348 participants from the Heart Protection Study. BACKGROUND: There have been claims that noncarriers of the KIF6 719Arg variant receive little...

Full description

Bibliographic Details
Main Authors:	Hopewell, J, Parish, S, Clarke, R, Armitage, J, Bowman, L, Hager, J, Lathrop, M, Collins, R
Format:	Journal article
Language:	English
Published:	2011

Similar Items

No impact of KIF6 genotype on vascular risk and statin response among 18,348 randomized patients in the heart protection study.
by: Hopewell, J, et al.
Published: (2011)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
by: Hopewell, J, et al.
Published: (2009)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
by: Hopewell, J, et al.
Published: (2011)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
by: Hopewell, J, et al.
Published: (2011)

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study.
by: Hopewell, J, et al.
Published: (2013)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
by: Parish, S, et al.
Published: (2012)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
by: Mihaylova, B, et al.
Published: (2009)

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
by: Link, E, et al.
Published: (2008)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
by: Emberson, J, et al.
Published: (2005)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
by: Bulbulia, R, et al.
Published: (2007)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
by: Emberson, J, et al.
Published: (2005)

Cardiovascular outcomes among participants with diabetes in the recent large statin trials.
by: Armitage, J, et al.
Published: (2004)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
by: Hopewell, J, et al.
Published: (2010)

Misrepresentation of statin safety evidence.
by: Armitage, J, et al.
Published: (2014)

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
by: Hopewell, J, et al.
Published: (2014)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy
by: Mangravite, L, et al.
Published: (2013)

A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
by: Mangravite, L, et al.
Published: (2013)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
by: Emberson, JR, et al.
Published: (2007)

The safety of statins in clinical practice.
by: Armitage, J
Published: (2007)

Lessons from the controversy over statins - Authors' reply.
by: Armitage, J, et al.
Published: (2016)

Safety and efficacy of statins - Authors' reply
by: Collins, R, et al.
Published: (2017)

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
by: Kearney, P, et al.
Published: (2008)

The Impact of Genetic Variants Related to LDL-cholesterol on Risk of Ischemic Stroke and Coronary Heart Disease
by: Hopewell, J, et al.
Published: (2012)

The effects of vascular and nonvascular adverse events and of extended-release niacin with laropiprant on health and healthcare costs
by: Kent, S, et al.
Published: (2016)

Benefits of reducing LDL cholesterol among 18,686 patients with diabetes: Meta-analysis of 14 radomized trials of a statin versus control
by: Kearney, P, et al.
Published: (2006)

Early comprehensive characterisation of the vascular response to statin treatment using MRI
by: Lee, J, et al.
Published: (2006)

Cholesterol, statins, and mortality - Reply
by: Lewington, S, et al.
Published: (2008)

C-reactive protein in the Heart Protection Study - Authors' reply
by: Emberson, J, et al.
Published: (2011)

Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2003)

Aspirin for primary prevention of vascular disease in people with diabetes.
by: Haynes, R, et al.
Published: (2009)

Cholesterol, statins, and mortality - Authors' reply
by: Lewington, S, et al.
Published: (2008)

Vascularizing the heart.
by: Riley, P, et al.
Published: (2011)

The regulation of KIF3A motor subunit by phosphorylation
by: Chen, Kunning
Published: (2018)

Characterisation of mitotic phosphorylation on chromokinesin KIF4A
by: Ang, Anthony Wei Tzerl
Published: (2015)

C-reactive protein in the Heart Protection Study Reply
by: Emberson, J, et al.
Published: (2011)

Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality
by: Parish, S, et al.
Published: (2010)

MRC/BHF Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2002)

New analyses of Heart Protection Study - Reply
by: Collins, R, et al.
Published: (2004)

Biomarkers of inflammation predict both vascular and non-vascular mortality in older men.
by: Clarke, R, et al.
Published: (2008)

Biomarkers of inflammation predict both vascular and non-vascular mortality in older men
by: Clarke, R, et al.
Published: (2008)